Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity
- 15 November 2024
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (101) , eadp7302
Abstract
T cell immunoglobulin and mucin domain–containing protein 3 (TIM-3) is an immune checkpoint that has critical roles in immune exhaustion. However, little is known about the mechanisms that regulate TIM-3 surface expression and turnover. Here, we report that human TIM-3 is palmitoylated by the palmitoyltransferase DHHC9 at residue cysteine 296 (Cys 296 ). Palmitoylation stabilized TIM-3 by preventing binding to E3 ubiquitin ligase HRD1, thereby suppressing its polyubiquitination and degradation. DHHC9 knockdown attenuated chimeric antigen receptor T (CAR-T) cell exhaustion, and a peptidic inhibitor of TIM-3 palmitoylation accelerated TIM-3 degradation and enhanced antitumor immunity mediated by CAR-T cells and natural killer (NK) cells. In hepatocellular carcinoma, DHHC9 expression correlated with TIM-3 expression in CD8 + T cells and NK cells, and high DHHC9 expression was associated with shorter survival in patients with high TIM-3. These findings demonstrate that palmitoylation of TIM-3 catalyzed by DHHC9 promotes its stability, resulting in immune exhaustion and impaired antitumor immunity.Keywords
This publication has 57 references indexed in Scilit:
- Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironmentBiomedicine & Pharmacotherapy, 2023
- Spatial distribution and functional analysis define the action pathway of Tim-3/Tim-3 ligands in tumor developmentMolecular Therapy, 2022
- GPS 5.0: An Update on the Prediction of Kinase-Specific Phosphorylation Sites in ProteinsGenomics, Proteomics & Bioinformatics, 2020
- Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1Molecular Cell, 2018
- The regulation of TIM-3 transcription in T cells involves c-Jun binding but not CpG methylation at the TIM-3 promoterMolecular Immunology, 2016
- Palmitoylacyltransferase Zdhhc9 inactivation mitigates leukemogenic potential of oncogenic NrasLeukemia, 2015
- T‐bet, a Th1 transcription factor regulates the expression of Tim‐3European Journal of Immunology, 2010
- Imaging the Lipidome: ω-Alkynyl Fatty Acids for Detection and Cellular Visualization of Lipid-Modified ProteinsACS Chemical Biology, 2009
- Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature, 2002
- Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsiesCancer, 1954